Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
BL-M11D1 in Relapsing acute myeloid leukemia: NCT06714591 Clinical Landscape Report 2026
16 October 2026
NCT06714591 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
CT-0991 in Relapsing acute myeloid leukemia: NCT06709131 Clinical Landscape Report 2026
16 October 2026
NCT06709131 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Elranatamab in Multiple Myeloma: NCT06711705 Clinical Landscape Report 2026
16 October 2026
NCT06711705 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metabolically Armed CD19 CAR-T cells(Leman Biotech ) in Systemic Lupus Erythematosus: NCT06711146 Clinical Landscape Report 2026
16 October 2026
NCT06711146 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-MM-BC1 in Multiple Myeloma: NCT06717113 Clinical Landscape Report 2026
16 October 2026
NCT06717113 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FD-001 in Acute Myeloid Leukemia: NCT06731699 Clinical Landscape Report 2026
16 October 2026
NCT06731699 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TolDC(University Hospital Antwerp) in Multiple Sclerosis: NCT06715605 Clinical Landscape Report 2026
16 October 2026
NCT06715605 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT0596 CAR-T Cell in Multiple Myeloma: NCT06718270 Clinical Landscape Report 2026
16 October 2026
NCT06718270 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IPG-11406 in Lupus Nephritis: NCT06717815 Clinical Landscape Report 2026
16 October 2026
NCT06717815 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivosidenib in Acute Myeloid Leukemia: NCT06717958 Clinical Landscape Report 2026
16 October 2026
NCT06717958 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT0596 CAR-T Cell in Plasma Cell Leukemia: NCT06730256 Clinical Landscape Report 2026
16 October 2026
NCT06730256 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Refractory acute myeloid leukemia: NCT06737523 Clinical Landscape Report 2026
16 October 2026
NCT06737523 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…